Multimodal Pain Management: Principles and Implementation

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Multimodal analgesia strategically combines two or more analgesic modalities (drug classes, techniques, or non-pharmacologic interventions) that target distinct pain mechanisms to achieve superior pain control while minimizing adverse effects from individual agents.
• Core drug classes utilized include opioids, NSAIDs, local anesthetics, alpha-2 agonists, NMDA antagonists (e.g., ketamine), paracetamol, and gabapentinoids, each acting at different stages of the nociceptive pathway from peripheral transduction to central perception.
• Preemptive analgesia, administering analgesics before a painful stimulus, is crucial for mitigating central sensitization and wind-up, thereby reducing the magnitude of postoperative pain and the required doses of individual agents.
• Effective implementation hinges on rigorous, species-specific pain assessment using validated scoring tools to guide drug selection, dose adjustment, and the determination of rescue analgesia criteria, with consistent monitoring of sedation, respiratory function, and organ perfusion.
• Adoption of multimodal protocols is variable across veterinary disciplines, with strong evidence and practice in small animal surgery, but behavioral barriers (inconsistent use of pain scoring) and dose standardization challenges persisting in some areas.
• Successful multimodal planning requires careful consideration of species-specific pharmacokinetics, contraindications (e.g., NSAID use in gastrointestinal surgery, alpha-2 agonist cardiovascular effects), and the integration of analgesic strategies within broader perioperative care bundles.

Multimodal pain management is the deliberate concurrent use of two or more analgesic drug classes, techniques, or nonpharmacologic interventions that act through different mechanisms to achieve pain control while reducing the dose and therefore the adverse effects of any single agent. This article examines the conceptual foundation of multimodal analgesia, the drug classes available to the veterinary practitioner, the evidence supporting integrated protocols, and the practical decisions involved in constructing and monitoring a balanced analgesic plan. It is written for practicing veterinarians and senior veterinary students who already command the basic pharmacology of individual analgesics and seek a structured framework for combining them across species and clinical contexts.

The clinical question this article answers is direct: when faced with a patient in pain, how does the clinician decide which analgesics to combine, in what order, by which routes, and with what monitoring? The answer draws on physiology, pharmacokinetics, and a growing body of veterinary and comparative outcome data. Multimodal protocols are now standard in small animal surgery, laboratory animal medicine, and equine practice, and the principles extend to exotic species and production animals within the limits of licensed products and withdrawal requirements.

At a Glance

The Scientific Rationale for Multimodal Analgesia

Nociception is not a single event but a cascade: transduction at the peripheral nociceptor, transmission along primary afferent fibers, modulation at the spinal cord dorsal horn, and perception in higher brain centers. Each stage offers distinct pharmacologic targets. A single drug class, no matter how potent, interrupts only one or two links in this chain. Opioids act primarily at spinal and supraspinal receptors to modulate transmission and perception. NSAIDs reduce peripheral prostaglandin synthesis and sensitization. Local anesthetics block sodium channels and prevent transmission entirely. Alpha-2 agonists produce analgesia through spinal and supraspinal receptor activation with additional sedation. NMDA receptor antagonists such as ketamine attenuate central sensitization and wind-up, the spinal hyperexcitability that follows sustained nociceptive input.

The clinical consequence of this physiology is that a patient receiving only an opioid retains intact peripheral sensitization and spinal wind-up. The opioid dose required to overcome these processes rises, and with it the risk of ileus, sedation, dysphoria, and respiratory depression. Combining a low opioid dose with an NSAID, a local anesthetic block, and a ketamine infusion targets the same pain at four points. The analgesic effect is additive or synergistic while the adverse effect profile of each drug remains dose dependent and therefore minimized.

Central sensitization deserves particular emphasis. Once established, it outlasts the inciting stimulus and amplifies subsequent input, which is why preemptive analgesia matters. Administering analgesics before surgical incision or traumatic injury reduces the magnitude of central sensitization and postoperative pain scores in multiple species. The practical implication is that the multimodal plan should begin before the painful stimulus, not after the patient has recovered from anesthesia and demonstrated pain behavior.

Evidence Base and Current Practice Patterns

Survey data from veterinary practice reveal a persistent gap between the theoretical case for multimodal analgesia and its routine implementation. A 2025 survey of veterinary professionals managing feline sterilization procedures found that only 20.5% of respondents used objective pain scoring systems preoperatively, and just 14.2% used them before discharge, despite the availability of validated feline pain scales and multimodal analgesic protocols. A parallel survey of United Kingdom practitioners performing spay surgery reported that colleagues implemented multimodal analgesia in only 43% of feline and 44% of canine procedures. These figures indicate that the barrier to multimodal pain management is not pharmacologic but behavioral: the drugs are available, the evidence supports their use, and the limiting factor is consistent adoption of structured protocols and pain scoring.

The laboratory animal field shows a different pattern. A 2022 FELASA working group survey of laboratory mouse analgesia found that 69% of respondents used multimodal regimens for surgical models, with opioids, predominantly buprenorphine, and NSAIDs, predominantly meloxicam and carprofen, as the most common combination. Local anesthetics, mostly lidocaine, were widely used in surgical models. The same survey documented wide variation in reported dose rates of meloxicam and carprofen, a finding that underscores the need for current formulary reference when constructing protocols.

Comparative outcome data support the clinical value of integrated protocols. A veterinary enhanced recovery after surgery program for dogs undergoing emergency laparotomy, incorporating multimodal analgesia alongside early goal-directed fluid resuscitation, antiemetic therapy, and early enteral nutrition, reduced perioperative complication rates and 15-day mortality from 20.7% in historical controls to 5% in protocol-managed dogs. The multimodal component cannot be isolated from the other interventions in such a program, but the magnitude of the improvement argues that systematic perioperative care, including balanced analgesia, changes outcomes.

Drug Classes and Integration Logic

The core drug classes available to the veterinary practitioner are opioids, NSAIDs, local anesthetics, alpha-2 agonists, NMDA antagonists, paracetamol, and the gabapentinoids. Each occupies a defined position in a multimodal plan.

Opioids remain the most extensively used systemic analgesics in perioperative care across species, a pattern documented in comparative surgical literature. Their potency and rapid onset make them the backbone of moderate to severe acute pain protocols. The choice among full mu agonists, partial agonists, and mixed agonist-antagonists depends on the expected pain intensity, the species, and the desired sedation level.

NSAIDs provide the anti-inflammatory component that opioids cannot. They reduce peripheral sensitization and are particularly valuable when inflammation is a major pain driver, as in orthopedic disease, dental disease, and soft tissue trauma. The evidence on NSAID safety in specific contexts requires attention. An experimental rat model of colonic anastomosis found that perioperative lornoxicam administration significantly decreased fibroblast ingrowth and mucosal reepithelialization at the anastomotic site on postoperative day three and increased deep reaching defects, necrosis, and microabscess formation on day seven, although it did not significantly increase anastomotic dehiscence. The clinical translation of this finding is that NSAID use in gastrointestinal surgery warrants a risk-benefit assessment, particularly when anastomotic healing is a concern.

Local anesthetics interrupt nociceptive transmission at the source. Epidural, spinal, and peripheral nerve blocks provide profound regional analgesia with minimal systemic drug exposure. Their inclusion in a multimodal plan reduces the systemic opioid requirement and improves recovery quality. The WSAVA Global Pain Council Guidelines and the AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats both endorse regional anesthesia as a component of balanced protocols for appropriate procedures.

Alpha-2 agonists contribute sedation, muscle relaxation, and analgesia through spinal and supraspinal mechanisms. They are commonly used as continuous rate infusions in dogs and cats to reduce inhalant anesthetic requirements and provide postoperative analgesia. Their cardiovascular effects, bradycardia and increased systemic vascular resistance, require monitoring in patients with cardiac disease.

Ketamine at subanesthetic doses blocks NMDA receptors and prevents central sensitization. It is most valuable in patients with severe or prolonged nociceptive input, such as major trauma, extensive surgery, or conditions associated with wind-up. Paracetamol provides a weak analgesic and antipyretic effect through central mechanisms distinct from NSAIDs and can be combined with them, though species differences in metabolism and toxicity must be respected.

Gabapentinoids, gabapentin and pregabalin, modulate calcium channel subunits and are used primarily for neuropathic and chronic pain. Their role in acute perioperative pain is less established, but they are increasingly included in protocols for patients with a neuropathic component to their pain.

Constructing a Multimodal Plan

The sequence of decisions in building a multimodal plan follows a consistent logic. First, assess the expected pain intensity of the procedure or condition using a validated species-specific pain scale. Second, identify the dominant pain mechanism: inflammatory, somatic, visceral, or neuropathic. Third, select one drug from each relevant class, choosing routes that complement instead of duplicate. Fourth, schedule administration so that preemptive analgesia precedes the painful stimulus. Fifth, define monitoring parameters and rescue analgesia criteria before the plan is implemented.

Pain assessment is the rate-limiting step in this process. Objective, validated pain scales exist for dogs, cats, and laboratory rodents, and their use is associated with improved analgesic administration. The WSAVA guidelines provide a framework for selecting and applying these tools across companion animal species. The practitioner who does not measure pain cannot adjust a multimodal plan rationally, and the survey data from feline and canine practice indicate that this is the most common point of failure.

Rescue analgesia must be specified in advance. A multimodal plan that does not define what happens when the patient scores above the treatment threshold is incomplete. The rescue agent should be from a different class than the primary analgesic, and the dose should be recorded in the patient record. Serial reassessment after rescue administration determines whether the plan requires escalation or revision.

Species and Context Considerations

The principles of multimodal analgesia apply across species, but the drug choices, routes, and monitoring parameters differ. Small animal practice has the deepest evidence base and the widest range of licensed products. Equine practice relies heavily on NSAIDs, opioids, and alpha-2 agonists, with regional techniques increasingly used for limb surgery. Laboratory animal medicine, as the FELASA survey demonstrates, has adopted multimodal regimens in surgical models, though dose standardization remains an issue. Exotic species, including rabbits, rodents, birds, and reptiles, present particular challenges: few products are licensed, metabolism varies widely, and pain assessment tools are less developed. Production animal practice must incorporate withdrawal periods and, in some regions, regulatory constraints on analgesic use in food animals, with the World Organization for Animal Health terrestrial standards providing international context for welfare and treatment expectations.

The evidence base for multimodal analgesia in chronic pain is less robust than for acute perioperative pain. The gabapentinoids and other adjuncts are used extensively in canine and feline osteoarthritis and neuropathic pain, but controlled trials comparing multimodal protocols against monotherapy are limited. The practitioner should therefore apply the same structured assessment and reassessment logic to chronic pain patients, adjusting the protocol based on objective functional outcomes and owner-reported behavior instead of assuming that a fixed combination will remain effective indefinitely.

Assessment and Pain Scoring in the Multimodal Framework

Pain scoring is the foundation on which a multimodal plan is built, adjusted, and discontinued. A validated composite pain scale should be applied at defined time points: before premedication, after recovery from anesthesia, at regular intervals during hospitalization, and immediately before discharge. The scale chosen must be species-appropriate and validated for the procedure and setting. For cats, objective scoring systems exist but are used inconsistently in practice, survey data from Ohio indicate that only 20.5% of respondents used an objective pain scoring system preoperatively, and only 14.2% used one before discharge. This gap between tool availability and clinical application represents a correctable failure point.

A practical scoring sequence includes observation from a distance, interaction with the patient, and palpation of the surgical site or affected region. Each domain contributes distinct information. Behavioral withdrawal, vocalization, and posture changes are useful in dogs and cats, but prey species such as rabbits and rodents may suppress overt pain behaviors, making grimace scales and activity monitoring more informative. The 2022 FELASA working group survey found that 98% of respondents assessed pain in laboratory mice, yet analgesic use varied widely by model type, with 92% providing analgesics for surgical models but only 34% for non-surgical models. This discrepancy suggests that assessment alone does not guarantee treatment, and that protocols should mandate analgesic provision instead of leave it to individual judgment.

Documentation should record the scale used, the numeric score, the time relative to procedure, and the intervention triggered by the score. A score above a predefined threshold should prompt rescue analgesia, and the response to rescue should be reassessed within 30 to 60 minutes. If the score does not decrease, the clinician must consider inadequate dosing, incorrect drug class selection, or a complication such as surgical site infection or seroma formation instead of simply repeating the same drug.

Selecting Drug Classes and Anticipating Interactions

The multimodal plan integrates drugs from different classes so that each agent acts at a distinct point in the pain pathway. Opioids provide central and spinal analgesia, non-steroidal anti-inflammatory drugs (NSAIDs) reduce peripheral and central sensitization through cyclooxygenase inhibition, local anesthetics block afferent transmission, alpha-2 agonists provide sedation and supraspinal analgesia, and adjuncts such as ketamine, gabapentin, and amantadine modulate wind-up and neuropathic components. The WSAVA Global Pain Council Guidelines endorse this multi-target approach as the standard of care for companion animals.

Drug selection is governed by patient status, not by habit. Hepatic or renal disease alters NSAID clearance and increases the risk of gastrointestinal and renal adverse effects. Coagulopathies preclude neuraxial blocks and increase bleeding risk with regional techniques. Cardiac disease may limit the use of alpha-2 agonists or require dose reduction. The MSD Veterinary Manual provides species-specific pharmacology and contraindication tables that should be consulted before finalizing a plan.

The order of administration matters. Premedication with an opioid and an alpha-2 agonist or benzodiazepine reduces the induction agent requirement and provides preemptive analgesia. Local anesthetic blocks performed before incision reduce central sensitization. An NSAID administered preoperatively or intraoperatively provides anti-inflammatory coverage that persists into the postoperative period. The AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats recommend that analgesic planning begin before the procedure, with drugs selected based on the anticipated tissue trauma, patient comorbidities, and the expected duration of pain.

Monitoring Parameters and Their Clinical Meaning

Monitoring during the perioperative period serves two purposes: detecting inadequate analgesia and detecting drug adverse effects. The two are not mutually exclusive, and a patient can experience both simultaneously.

A patient who is tachycardic and hypertensive after recovery may be in pain, but the same signs can indicate hypovolemia, hyperthermia, or emergence delirium. The multimodal plan should include a differential list for each abnormal parameter, and the clinician should address the most likely cause first. If pain is suspected, a small dose of an opioid can serve as both a diagnostic test and a therapeutic intervention. If the parameter does not improve, the diagnosis of pain should be reconsidered.

Adjusting the Plan in Response to Patient Status

The multimodal plan is not static. It must be revised when the patient's condition changes, when the procedure is more extensive than anticipated, or when a drug class is contraindicated by new information. For example, an NSAID should be withheld or discontinued if postoperative azotemia develops, and an alternative such as a full mu-opioid agonist or a local anesthetic infusion should be substituted. The decision to escalate from a partial agonist such as buprenorphine to a full agonist such as morphine or methadone should be based on pain scores that remain above threshold despite appropriate dosing.

In emergency laparotomy in dogs, a structured enhanced recovery protocol that includes multimodal analgesia, early goal-directed fluid resuscitation, and early enteral nutrition reduced perioperative complication rates and 15-day mortality from 20.7% to 5% compared with historical controls. This finding supports the integration of analgesic planning into a broader perioperative care bundle instead of treating analgesia as an isolated intervention.

Species differences alter the correct choice. Cats have limited capacity for glucuronidation, which affects the metabolism of some NSAIDs and opioids. Rabbits and rodents require careful dose calculation because of high metabolic rates and the risk of gastrointestinal stasis with NSAIDs. Food animals present additional constraints: drug residues and withdrawal periods must be checked against current label and formulary references, and extralabel use requires a valid veterinary-client-patient relationship and compliance with regional regulations. The WOAH Terrestrial Animal Health Code addresses welfare standards for animals in production systems, and analgesic protocols should align with these expectations where applicable.

Rescue Analgesia and Escalation Pathways

Every multimodal plan should include a predefined rescue protocol. The rescue drug should be from a different class than the primary agents, or a higher-potency agent within the same class. For example, if the baseline plan uses buprenorphine and an NSAID, rescue could be methadone or morphine. If the baseline plan uses a constant-rate infusion of lidocaine and ketamine, rescue could be a bolus of fentanyl or a full mu-agonist.

The rescue protocol should specify the dose, the route, the reassessment interval, and the criteria for escalating to a higher level of intervention. Escalation options include adding a regional block, increasing an infusion rate, or converting to a continuous opioid infusion. If two rescue interventions fail to reduce the pain score, the clinician should investigate for surgical complications, including infection, ischemia, or nerve injury, instead of continuing to escalate analgesic doses.

The evidence base for specific rescue protocols is limited. A systematic review of perioperative pain management in cardiac surgery found that opioids remain the most extensively used therapy, with few trials investigating alternatives such as paracetamol. This pattern likely reflects the broader veterinary literature, where opioid-based rescue remains the default despite interest in opioid-sparing strategies. Clinicians should therefore base rescue decisions on patient response and pain scores instead of on a fixed protocol, and should document the rationale for each escalation step.

Recognized Complications and Early Detection

Multimodal regimens fail through predictable mechanisms. The most common is cumulative toxicity from drugs that share metabolic or excretory pathways. NSAIDs combined with other protein-bound or renally cleared agents can produce silent renal injury, particularly in hypovolemic patients. Early detection requires serial assessment of perfusion parameters, urine output, and renal biochemistry instead of reliance on a single postoperative sample.

Opioid-related complications, including ileus, urinary retention, and dysphoria, remain under-recognized because they are attributed to the surgical procedure itself. A patient that is tachycardic, restless, and vocalising 4 hours after buprenorphine may be experiencing inadequate analgesia or opioid dysphoria. The discriminating observation is response to a small additional dose of the same opioid: improvement supports pain, worsening supports dysphoria.

Local anesthetic toxicity presents with perioral numbness, muscle fasciculations, seizures, or arrhythmias. It is most often seen after repeated boluses through an indwelling catheter or after inadvertent intravascular injection. Detection depends on documenting total drug administered per kilogram per hour, also the most recent bolus.

The table below summarizes common failure modes and the observations that distinguish them.

Common Errors and Corrective Actions

Less experienced clinicians frequently construct plans that are broad but shallow: they administer an NSAID, an opioid, and a local block, yet fail to consider duration of action relative to the expected pain trajectory. A single dose of an opioid with a 4-hour duration does not cover a 12-hour recovery period. The corrective action is to map each drug's duration against the anticipated pain curve and schedule redosing before pain escalates.

A second error is treating pain scoring as a checkbox instead of a clinical decision tool. Survey data from feline sterilization procedures show that only a minority of practices use objective pain scoring systems at any point in the perioperative period, despite their availability. The corrective action is to select one validated scale per species, use it at fixed intervals, and record the score in the medical record so trends become visible.

A third error is discontinuing analgesia at discharge without an owner-observable plan. The same feline survey found that most ovariohysterectomy patients were discharged with medication, but owner education on pain recognition was inconsistent. The corrective action is to provide written instructions that describe specific behaviors to monitor and a contact pathway if those behaviors appear.

A fourth error, more common in emergency settings, is omitting non-pharmacologic components of the plan. Enhanced recovery protocols that include early enteral nutrition, antiemetic therapy, and goal-directed fluid therapy reduce perioperative complications in dogs undergoing emergency laparotomy compared with conventional management. Analgesia is one element of a broader perioperative strategy, not a substitute for it.

Limitations of the Evidence and Areas of Disagreement

The evidence base for multimodal analgesia in veterinary medicine is uneven. Most published data derive from small animal elective surgery, with far less information available for exotic species, production animals, and equine patients. A 2022 survey of laboratory mouse analgesia found that 69% of respondents used multimodal regimens, but dose rates for commonly used NSAIDs varied widely, reflecting the absence of standardized references.

Expert opinion diverges on several points. The role of NSAIDs in patients with compromised gastrointestinal healing remains contested. Experimental work in rats showed that lornoxicam adversely affected histologic parameters of colonic anastomotic healing, although it did not significantly increase dehiscence. Whether this translates to clinically relevant outcomes in dogs and cats after intestinal surgery is unresolved, and clinicians must weigh analgesic benefit against theoretical risk.

The value of pre-emptive versus preventive analgesia continues to generate debate. Some authors argue that pre-incisional administration reduces central sensitization, while others contend that the clinical benefit is marginal once a multimodal plan is in place. The WSAVA Global Pain Council Guidelines acknowledge this uncertainty and recommend individualising the timing of analgesic administration based on procedure and patient status.

Referral, Consultation, and Reporting

Referral is warranted when pain cannot be controlled despite escalation through two drug classes, when the patient develops signs of neuropathic pain such as allodynia or hyperalgesia, or when regional anesthetic techniques are required that exceed the clinician's training. Specialist consultation with a veterinary anesthetist or pain specialist is appropriate for patients with concurrent organ dysfunction that complicates drug selection, and for chronic pain cases where the evidence base for specific combinations is limited.

Laboratory involvement is indicated when monitoring reveals unexplained elevations in renal or hepatic parameters, when coagulopathy is suspected, or when therapeutic drug monitoring is needed for drugs with narrow therapeutic indices. The MSD Veterinary Manual provides species-specific guidance on normal reference intervals and the interpretation of abnormal values.

Regulatory reporting obligations vary by jurisdiction and species. In production animals, withdrawal periods must be observed and recorded, and the responsible veterinarian must ensure that treated animals do not enter the food chain prematurely. The World Organization for Animal Health terrestrial standards address the responsible use of antimicrobials and other veterinary products in food-producing animals. In companion animal practice, adverse drug reactions should be reported to the relevant national pharmacovigilance scheme, particularly for newly introduced products or off-label combinations. The American Veterinary Medical Association provides practice resources on adverse event reporting and professional obligations.

Frequently Asked Questions

How do I build an effective multimodal plan when cost or drug availability is limited?

Prioritize by mechanism and duration of action. An NSAID plus a local anesthetic technique provides two distinct mechanisms and is often the most economical starting point. When opioids are unavailable or unaffordable, alpha-2 agonists, ketamine, or amantadine can partially substitute, though each has different coverage profiles. The WSAVA Global Pain Council Guidelines provide tiered recommendations that help clinicians select agents based on expected pain severity and available resources. For procedures where a full protocol is impossible, choose the drug class best matched to the dominant pain type, then add a second agent only if it addresses a different pathway. Document the limitation and reassess the patient frequently, since rescue requirements will rise when coverage is incomplete.

What should I do when locoregional anesthesia equipment or expertise is unavailable?

Systemic adjuncts become proportionally more important. Ketamine at subanaesthetic doses, lidocaine infusions, and alpha-2 agonists can narrow the gap left by absent regional blocks. For simple procedures, infiltration of local anesthetic at the incision line requires only a syringe and needle, and this should be used whenever feasible. The AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats emphasize that technique selection should match available skills and equipment, and that a simple block performed reliably outperforms an advanced block attempted poorly. Refer cases where a regional technique would substantially change outcomes, and consider whether referral is appropriate before surgery instead of after complications develop.

How does the multimodal approach differ when managing pain in laboratory animals or production species?

Regulatory frameworks and withdrawal periods constrain drug selection more heavily than in companion animal practice. In laboratory mice, survey data show that most institutions use multimodal regimens, but dose ranges for common NSAIDs vary widely across institutions, which complicates protocol standardization and case comparison. The 2022 FELASA survey of pain assessment and analgesic use in laboratory mice documents this variability and the reliance on buprenorphine and NSAIDs as primary agents. For food animals, every drug choice must be checked against jurisdiction-specific withdrawal requirements, and the WOAH terrestrial animal health standards frame welfare obligations within production medicine. Species-specific metabolism, such as altered NSAID half-lives in rabbits or rodents, requires dose adjustment and prolonged monitoring intervals.

What documentation should accompany a multimodal pain plan?

Record the pain score used, the score value at each assessment point, every drug administered with route and time, and the patient response to each intervention. Note why specific drug classes were selected or excluded, particularly if an opioid was omitted or a NSAID was withheld due to contraindications. The MSD Veterinary Manual advises that analgesic records should permit retrospective evaluation of whether the plan achieved its targets. Include a rescue protocol in the written record so that any clinician or nurse covering the case knows the escalation pathway. For discharge, provide written instructions that name each medication, its dose, frequency, and the specific signs that should trigger a call back to the clinic.

How should I explain a multimodal plan to a client who is concerned about polypharmacy?

Frame the plan around targeted coverage instead of drug count. Explain that each medication addresses a different source of pain, which allows lower doses of each and reduces reliance on any single agent. Use an analogy such as managing multiple contributing factors instead of one cause. The AVMA practice resources support client communication that emphasizes safety monitoring and expected outcomes. Be explicit about which drug provides baseline comfort, which covers breakthrough pain, and which reduces inflammation. Address cost transparency early, and discuss which components are essential versus optional if the client has financial constraints. Provide written aftercare instructions and confirm the client can identify the signs of inadequate pain control before they leave the clinic.

When should I escalate from a multimodal plan to referral or specialist consultation?

Escalate when pain scores remain above the treatment threshold despite two sequential adjustments, when rescue analgesia is required more frequently than the protocol anticipates, or when the patient develops complications such as ileus, dysphoria, or suspected opioid-related hyperalgesia. Refer early for regional anesthesia techniques that require advanced skills, for patients with complex comorbidities that alter drug metabolism, or when the clinician lacks experience with the species involved. The WSAVA Global Pain Council Guidelines recommend that persistent pain beyond the expected procedural duration warrants investigation for surgical complications instead of simple dose escalation. Document the referral reason, the treatments already attempted, and the patient response to each, so the receiving clinician can continue the plan without repeating failed interventions.

Related Clinical & Scientific Guides

• Anesthetic Machine Leak Testing and Pressure Checks: A Step-by-Step Protocol
• Anesthetic Depth Assessment: Reflexes, Eye Position, and Ventilation
• Anesthesia for Patients with Obesity: Challenges and Solutions

References and Further Reading

• Current practices of pain assessment and analgesic use in laboratory mice: A 2022 FELASA Working Group survey.. 2025.
• Effects of Lornoxicam on Anastomotic Healing: A Randomized, Blinded, Placebo-Control Experimental Study.. 2016.
• Survey study based on the assessment and management of pain in cats by veterinary professionals after elective sterilization procedures.. 2025.
• A Survey Study on the Current Veterinary Practice and Attitudes to Anesthesia and Analgesia for Spay Surgery in the United Kingdom.. 2025.
• Veterinary Enhanced Recovery After Surgery (Vet-ERAS) Program in Dogs Undergoing Emergency Laparotomy.. 2025.
• Perioperative pain management in cardiac surgery: a systematic review.. 2018.
• AAHA Anesthesia and Monitoring Guidelines for Dogs and Cats. AAHA.
• WSAVA Global Pain Council Guidelines. WSAVA.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Anesthetic Complications: Recognition and Initial Management
• Anesthesia for Patients with Skin Disease: Wound Management
• Anesthetic Complications in Rabbits: Emergency Management
• Brachycephalic Airway Syndrome and Anesthetic Management
• Equine Anesthetic Recovery: Complications and Management Strategies

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.